Elsevier

Health Policy

Volume 86, Issue 1, April 2008, Pages 85-96
Health Policy

An estimate of lifelong costs and QALYs in renal replacement therapy based on patients’ life expectancy

https://doi.org/10.1016/j.healthpol.2007.10.002Get rights and content

Abstract

Objectives

To estimate lifelong costs and quality adjusted life years (QALYs) of hemodialysis (HD), peritoneal dialysis (PD) and renal transplantation (Tx) in Greece, based on individual patient life expectancy.

Methods

A nationally representative patient sample on each modality, HD: N = 642, PD: N = 65 and Tx: N = 167, was self-administered the SF-36 Health Survey, from which the preference-based SF-6D utility index was derived. Lifelong QALYs were estimated from literature-based expected remaining life years according to age, gender and modality. Cost analyses were performed from the perspective of the health system. Costs and QALYs were discounted at 5% and sensitivity analyses were performed.

Results

Estimated lifelong QALYs were 4.37 (HD), 3.94 (PD) and 16.11 (Tx) (P < 0.001). Annual HD and PD costs per patient were estimated at €36,247 and €30,719 respectively. For Tx, average 1st year, 3-year and lifelong (undiscounted) costs were €31,714, €43,275 and €151,274 respectively. Cost per QALY was higher in HD (€60,353) compared to PD (€54,504) and 1st year Tx (€45,523).

Conclusions

HD is used by 75% of the Greek ESRD patients, hence cost-saving efforts must be intensified. Reconsidering supply and reimbursement policies for dialyzers and drugs, establishing satellite dialysis units and adopting telemedicine in remote areas could be explored. Wider use of PD is also in the direction of increasing cost-effectiveness. Finally, efforts are required for disseminating the idea of organ donation.

Introduction

Quality adjusted life-years (QALYs) are a measure of health status which account for both quality and duration of survival in a single outcome measure and express health status in terms of well years of life [1]. Quality adjustment is based on a set of values or weights (utilities), one for each possible health state, that reflect the relative preference of the individual for that health state relative to others. In cost utility analyses (CUA), the incremental cost of a program, considered from a particular viewpoint, is compared to the incremental health improvement – measured in QALYs – attributable to the program. CUA has been used to assess health technologies and compare treatment strategies, to assess the benefits of health interventions and in the decision analysis field. Review studies are available in the literature [2].

In end-stage renal disease (ESRD), the modalities available for treatment are hemodialysis (HD), peritoneal dialysis (PD) and renal transplantation (Tx), with the latter globally recognized as the best option, both in terms of costs and outcomes. Compared to HD, PD has some noted advantages such as better preserved residual renal function, delaying the need for blood access sites and reducing the risk of various cross-infections. It is generally preferred for home therapy and for patients with diabetes, cardiovascular problems or HIV infection, providing that patients are medically fit and willing to participate actively in their treatment [3]. On the other hand, HD is by far the most frequently used modality and is typically administered three times a week in dialysis facilities. Generally patients stay on HD longer than PD and experience fewer adverse incidents.

Renal replacement therapy (RRT), for ESRD, has undoubtedly been among the first medical interventions to be assessed with regard to its cost and outcomes. This is related to the large and rapidly increasing number of potential beneficiaries of such treatments, in conjunction to the large treatment costs. In Greece, for example, almost 10,000 patients are on some form of RRT with 75% on HD, 8% on PD and the rest have been transplanted. The augmentation of the RRT “pool” (also considering patient deaths) is close to 8% per year. The Greek estimate of €240 for the average cost of a dialysis session [4] implies that the aggregate annual economic impact exceeds 250 million Euros.

Despite increasing renal transplantation and advances in dialysis having contributed to improved patient survival, health-related quality of life (HRQOL) in this disease group is much lower than in the general population [5], [6]. Concerning treatment methods, it is clear that Tx patients have a better HRQOL than their dialysis counterparts [7], [8]. Contrarily, many studies comparing HD and peritoneal PD have not concluded on the superiority of either, with respect to HRQOL [9], [10]. In terms of survival, successful transplant provides a better overall outcome compared to dialysis and increased life expectancy. Although transplant recipients initially face an increased risk of death, ultimately the long-term mortality risk is significantly less compared to dialysis patients [11], [12], due to better immunosuppressive medication, organ procurement, patient preparation and surgical technique.

The majority of studies on the cost-effectiveness of ESRD treatment have used a combination of empirical data and literature-based evidence or estimations [13]. Similarly, the present study uses empirical quality-of-life data to estimate utilities, combined with literature-based survival data to calculate QALYs. Cost estimates for HD and PD are derived via a micro-costing analysis performed within the study, whereas the cost of Tx was extracted from an official Greek report. This study constitutes the first, to our knowledge, cost utility analysis of ESRD treatment methods based on expected remaining life years. Lifelong QALYs were estimated using SF-6D utilities derived from the generic SF-36 Health Survey, which was administered to a large and representative sample of the Greek ESRD population. Lifelong treatment costs for HD, PD and Tx were estimated in terms of annual costs, which were extrapolated over each patient's expected remaining lifetime.

Section snippets

Sample and data collection

The sample was comprised of RRT patients: (i) on in-center HD, (ii) on home PD or (iii) successfully transplanted. All such patients enlisted in the archives of the Hellenic Renal Registry were eligible participants, providing they were at least 18 years old, they had sufficient knowledge of Greek for self-administration of a survey containing the SF-36 and common sociodemographic and disease-related questions, and were physically and mentally capable of completing the survey with minimal

Results

Socio-demographic and health-related characteristics of the sample are given in Table 1. According to modality, mean ages were 58.1 (HD), 58.7 (PD) and 43.7 (Tx), with the latter significantly different (P < 0.01) from the two dialysis groups. Overall, 61.3% were male and 38.7% had completed only primary school. Most patients were married and 44.6% were currently employed (mostly transplant patients). In the HD and PD groups, 35.1% were on the transplant list, whereas approximately 10% had

Discussion

Interestingly, the first study to address QALYs, although not explicitly using the same term, was in the field of nephrology and concluded that transplanted patients experience a quality of life approximately 25% better than their dialysis counterparts [27]. Since then, many QALY studies have been published and according to a recent literature review of studies based on actual measurements of patients’ HRQOL [28], the SF-6D was used in 5% of them. This figure is encouraging, considering that

Conclusions

Results from this and similar studies could help to initiate a campaign in favor of organ donation. No previous economic evaluation has disputed that renal transplant is the most cost-effective RRT method, however it is usually limited by the number of donated kidneys available. This situation is unfortunately more persistent in Greece where it is impossible to meet demands for kidneys with only 6.5 donors per million population, resulting in 10-year (or longer) waiting lists. Helping to

Acknowledgements

We appreciate the help provided by Dr. John Boletis – President of the Hellenic Society of Nephrology – and Dr. Georgios Skoutelis for their help in collecting patient data and for willingly sharing their expertise with us. We are grateful to the Board of Directors of the Hellenic National Transplant Organization for providing the interim cost report. We also thank A. Mazaraki, N. Motsios and E. Patsia – M.Sc. students of the Hellenic Open University – for collecting dialysis cost data.

References (57)

  • P.A. McFarlane et al.

    The quality of life and cost utility of home nocturnal and conventional in-center hemodialysis

    Kidney International

    (2003)
  • Y. Teerawattananon et al.

    Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand

    Value in Health

    (2007)
  • M.F. Drummond et al.

    Methods for the economic evaluation of health care programmes

    (1997)
  • F. Mignon et al.

    Why so much disparity of PD in Europe?

    Nephrology Dialysis Transplantation

    (1998)
  • N. Kontodimopoulos et al.

    A socio-economic evaluation of hemodialysis and peritoneal dialysis in Greece

    International Journal of Healthcare Technology and Management

    (2005)
  • C.M. Gudex

    Health-related quality of life in end-stage renal failure

    Quality of Life Research

    (1995)
  • R.G. Simmons et al.

    Quality of life and rehabilitation differences among four end-stage renal disease therapy groups

    Scandinavian Journal of Urology and Nephrology

    (1990)
  • R. Gokal

    Quality of life in patients undergoing renal replacement therapy

    Kidney International

    (1993)
  • N.G. Kutner et al.

    Health status and quality of life reported by incident patients after 1 year on hemodialysis or peritoneal dialysis

    Nephrology Dialysis Transplantation

    (2005)
  • R.A. Wolfe et al.

    Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant

    New England Journal of Medicine

    (1999)
  • G.C. Oniscu et al.

    Impact of cadaveric renal transplantation on survival in patients listed for transplantation

    Journal of the American Society of Nephrology

    (2005)
  • J.E. Ware et al.

    The MOS 36-item short-form health survey (SF-36). Conceptual framework and item selection

    Medical Care

    (1992)
  • ERA-EDTA Registry. ERA-EDTA Registry 2003 Annual Report. Academic Medical Center: Amsterdam, The Netherlands,...
  • J.M. Miyamoto et al.

    Parameter estimates for a QALY utility model

    Medical Decision Making

    (1985)
  • M.R. Gold et al.

    Cost-effectiveness in health and medicine

    (1996)
  • Hellenic National Transplant Organization. Interim report on the proposed reimbursement of organ transplants in Greece....
  • M. Weinstein et al.

    Foundations of cost-effectiveness analysis for health and medical practices

    New England Journal of Medicine

    (1977)
  • K. Claxton et al.

    Discounting and cost-effectiveness in NICE—stepping back to sort out a confusion

    Health Economics

    (2006)
  • Cited by (84)

    • Kidney Transplantation in the Elderly

      2017, Kidney Transplantation, Bioengineering, and Regeneration: Kidney Transplantation in the Regenerative Medicine Era
    • Estimating Health-State Utility Values in Kidney Transplant Recipients and Waiting-List Patients Using the EQ-5D-5L

      2017, Value in Health
      Citation Excerpt :

      To conduct multivariable regression analyses to understand patient and treatment factors associated with variations in health-state utility values among kidney transplant recipients and waiting-list patients that can then be used to inform quality adjustment of life-years in cost-effectiveness evaluations. Cost-effectiveness analyses involving patients with ESRD have been undertaken to address a wide range of decision problems, including comparisons of dialysis versus transplantation [5–9], alternative dialysis modalities or initiation strategies [10–12], alternative approaches to kidney allocation [13], and different immunosuppressive therapies after transplantation [14–16]. Given that there may be considerable variation among cost-effectiveness analyses in terms of the target population or the data available to researchers on patient characteristics, we present utility values for a range of potential modeling needs.

    • Health-Related Quality of Life in Home Dialysis Patients Compared to In-Center Hemodialysis Patients: A Systematic Review and Meta-analysis

      2020, Kidney Medicine
      Citation Excerpt :

      A total of 46 articles was eligible for critical appraisal.82-127 The following articles presented overlapping patient data and were appraised as one: Bujang et al91 and Liu et al,92 Chkhotua et al94 and Maglakelidze et al,95 Griva et al103 and Yang et al,104 2 articles by Kontodimopoulos111,112 and 2 articles by Theofilou,120,121 leaving 41 studies for analysis. Characteristics of the included studies are described in Table 1.

    View all citing articles on Scopus
    View full text